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Abstract 
The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes 
across the globe. A significant proportion of adult patients require hospitalisation and may 
develop severe life-threatening complications. Children, on the other hand, can carry and 
transmit the virus, but usually do not develop severe disease. Mortality in the paediatric 
age-group is relatively low. Differences in virus containment and clearance, as well as 
reduced inflammation-related tissue and organ damage may be caused by age-specific 
environmental and host factors. Since severe complications in adults are frequently caused 
by uncontrolled immune responses and a resulting “cytokine storm” that may be controlled 
by targeted blockade of cytokines, previously established treatment with 
immunosuppressive treatments may indeed protect children from complications. 
 
Mini Review 
SARS-CoV2 is the pathogen causing COVID-19, a pandemic threatening millions of lifes 
globally. While in most individuals SARS-CoV2 infections are unapparent or associated with 
mild to moderate symptoms, as many as 10-20% develop severe or life-threatening 
disease1. 
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Surprisingly for an air-borne viral infection, the number for children diagnosed with COVID-
19 is relatively small (2.1% of 42.672 confirmed COVID-19 cases in China were children and 
young people (<19 years)), and disease-associated mortality among children is low2,3 (table 
1). 
Molecular studies targeting the pathophysiology of COVID-19 are sparse, but clinical and 
molecular parallels with related coronaviruses (SARS-, MERS-CoV) may be extrapolated. 
Infection and immune evasion -- Both SARS-CoV and SARS-Cov2 use ACE2 as entry receptor 
facilitating infection. Reflecting common organ involvement, ACE2 is expressed on 
pulmonary and intestinal epithelial cells1,4. As ACE2 is only expressed on a small subset of 
immune cells, other receptors and/or phagocytosis of virus-containing immune complexes 
may be involved in their infection1,5,6. 
SARS-CoV and SARS-CoV2 share the potential to escape the host’s immune response 6. 
Usually, RNAs viruses, including coronaviruses, are detected by endosomal TLR-3 and 7 
and/or cytoplasmic RNA sensors RIG-I and MDA5. TLR-3 and -7 promote nuclear shuttling of 
transcription factors NFκB and IRF3, while RIG-1/MDA5 ligation results in activation of IRF3.  
This triggers increased expression of type 1 interferons (T1IFN) (through IRF3) and other 
innate pro-inflammatory cytokines (IL-1, IL-6, TNF-α through NFκB)6,7. These induce an “anti-
viral state” and innate and adaptive immune cell responses which contribute to pathogen 
containment and clearance. Novel coronaviruses can escape these mechanisms by altering 
ubiquitination and degradation of the RIG-I/MDA5 adaptor molecule mitochondrial 
antiviral-signalling protein (MAVS), and inhibition of the nuclear translocation of IRF3 and 
TNF receptor-associated factors (TRAF)3 and 6 which induce NFκB signalling8. Furthermore, 
SARS-CoV and SARS-CoV-2 can counteract T1IFN through inhibition of STAT transcription 
factor phosphorylation7. 
COVID-19 associated cytokine storm -- Several clinical and laboratory features of COVID-19 
are associated with poor outcomes. Early studies from China linked cytopenias (leukopenia, 
lymphopenia, anaemia, thrombcytopenia) and elevated inflammatory parameters (IL-6, CRP, 
ESR) with unfavourable outcomes, suggesting cytokine storm syndrome in these patients 9. 
ICU dependency in particular was associated with increased plasma levels of innate 
chemokines IP-10, MCP-1, MIP-1A, and the pro-inflammatory cytokine TNF-α10. 
Though seemingly contradictory to aforementioned immune evasion through reduced 
cytokine expression, enhanced innate immune activation promotes morbidity and mortality 
in COVID-19. However, possible contributors to uncontrolled inflammation are cell damage 
and death as a result of viral replication11. In SARS-CoV infected mice, innate immune cells 
are recruited to the site of infection, where they induce strong inflammatory responses that 
further promote tissue damage and systemic inflammation12. 
Another mechanism contributing to poor outcomes may be antibody-dependent 
enhancement which is caused by early antibody production. Resulting virus-containing 
immune complexes promote cellular uptake of virus particles through Fcγ receptors. This 
may result in persistent viral replication in cells (including antigen-presenting cells), and 
immune complex mediated inflammation and damage13-15. Indeed, blood vessel occlusion 
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and infarctions have been reported in COVID, and show histopathologic features associated 
with immune complex vasculitis12. 
Why do children not get sicker? -- Currently, it is not known why children usually develop 
mild/moderate disease and only rarely develop cytokine storm syndrome (table 1). Several 
contributors may alter risk in children: 
i) Children are not travelling for business, reducing exposure to people. This may 
have played a role at the beginning of the pandemic. 
ii) While pathogen clearance may be reduced in adults, particularly in individuals at 
risk (elderly patients, diabetics, etc.)6,10, children have fewer comorbidities, 
including obesity. 
iii) Different immune response compared to adults, including strong innate and 
weaker adaptive immune responses. This may contribute to effective virus 
containment/clearance and/or reduced secondary lymphocyte-mediated 
inflammation16. 
iv) Local microbiomes, co-infections (and co-clearance) with other viruses, and/or 
immune priming to coronavirus infections as a result of frequent/constant 
exposure may help children to overcome SARS-CoV2 more effectively. 
v) As ACE2 is essential for epithelial cell infection, but also controls pulmonary 
inflammation and repair, variable ACE2 expression patterns may affect disease 
susceptibility and progression17,18. 
Risk for patients receiving immunosuppressive treatment -- Coronaviruses, including SARS-
CoV2 are “masters” of immune evasion, which contributes to uncontrolled virus replication 
and delayed but significant pro-inflammatory cytokine responses. While most children and 
young people effectively control infections and less frequently develop severe disease, 
patients receiving immune modulating treatments may have reduced ability to do so. 
Reassuringly, in a cohort of  200 liver transplant patients on immune suppressive treatment, 
only three tested positive for SARS-CoV2 and none developed relevant disease19. 
There are no evidence-based, approved treatments for COVID-19 and/or associated 
cytokine storm syndromes. Though children receiving immunosuppressive treatment may 
be at an increased risk for SARS-CoV2 infections, immunosuppression may protect from 
complications. Antimalarial treatments (chloroquine/hydroxychloroquine) may prevent 
infection through endocytosis. Classical and/or biologic DMARDs (particularly IL-6 and IL-1 
blockers) may control pro-inflammatory cytokine expression and limit tissue/organ damage. 
Delayed activation of adaptive immune responses may be of benefit, as  early antibody 
production may promote infection of immune cells and/or cause immune complex 
mediated pathology15. 
Conclusions – While data on COVID-19 is limited, children appear to be protected from 
severe disease. Paediatric Rheumatology Societies, including the Paediatric Rheumatology 
European Society (https://www.pres.eu/news/newsstory.html?id=29), recognize that 
discontinuation of immune modulating treatment may result in disease flares. In the 
absence of symptoms, immune modulating treatment should therefore be continued and 
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changes should only be made under close monitoring by the responsible clinical service. 
International collaboration is needed to safely assess individual risk in vulnerable patient 
groups. Until reliable data is available, close clinical monitoring and social distancing should 
be prioritized, but the collection of prospective data is required to improve the evidence 
base. 
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Table 1: Disease severity and laboratory findings in children with COVID-19. 
Sour
ce 
Cai 
et a. 
Cai 
et al. 
Chen 
et al. 
Feng 
et al. 
Wan
g et 
al. 
Zeng 
et al. 
Zhan
g et 
al. 
Liu 
et al. 
Kam 
et al. 
Chan 
et al. 
Zhan
g et 
al. 
Zhao 
et al. 
Sun 
et al. 
20 
Li et 
al. 21 
Su et 
al. 22 
Qiu 
et al. 
23 
Lin 
et al. 
24 
Zhen
g et 
al. 25 
Don
g et 
al. 3 
Summarised in Henry et al. 2       CDC 
data 
No 
of 
case
s  
10 1 1 15 31 1 1 1 1 1 2 1 8 2 9 36 1 25 2143 
Age 
(me
dian; 
rang
e) 
6yr 
(3mo
-
11yr) 
7yr 13m
o 
12yr 7yr 
(6mo
-
17yr) 
2wk 3mo 7yr 6mo 10yr 14m
o 
(twin
s) 
13yr 5yr 
(2mo
-
15yr) 
4yr 
(4yr) 
3.6yr 
(11m
o-
9yr) 
8.3 
(1-
16yr) 
7yr 3yr 
(2-
9yr) 
7yr 
(2-
13yy
r) 
Regi
on 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Sing
apor
e 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Chin
a 
Male
s 
4 
(40%
) 
1 
(100
%) 
1 
(100
%) 
5 
(33%
) 
15 
(48%
) 
1 
(100
%) 
0 1 
(100
%) 
1 
(100
%) 
1 
(100
%) 
0 1 
(100
%) 
6 
(75%
) 
1 
(500
%) 
3 
(33%
) 
23 
(64%
) 
0 14 
(56%
) 
1213 
(56.6
%) 
Sym
pto
ms 
10 
(100
%), 
mild 
1 
(100
%), 
mild 
1 
(100
%), 
mild 
3 
(20% 
), 
mild 
27 
(87%
), 
mild 
1 
(100
%), 
mild 
1 
(100
%), 
mild 
1 
(100
%), 
mild 
0 0 2 
(100
%), 
mild 
1 
(100
%), 
mild 
8 
(100
%), 
seve
re or 
critic
al 
2 
(100
%), 
mod
erat
e 
3 
(33%
), 
mild 
to 
mod
erat
e 
36 
(100
%), 
17 
(47.2
%) 
mild, 
19 
(52.8
%) 
mod
erat
e 
1 
(100
%), 
mild 
25 
(100
%), 8 
(32)
mild, 
15 
(60%
) 
mod
erat
e, 2 
(8%) 
seve
re 
2047 
(94.9
%), 
1091 
(50.9
%) 
mild, 
831 
(38.8
%) 
mod
erat
e, 
112 
(5.2
%) 
seve
re, 
13 
(0.6
% 
critic
al) 
Ches
t 
radi
ogra
phic 
chan
ges 
4 
(40%
) 
1 
(100
%) 
1 
(100
%) 
9 
(60% 
) 
14 
(45% 
) 
1 
(100
%) 
1 
(100
%) 
1 
(100
%) 
0 1 
(100
%) 
1 
(50%
) 
1 
(100
%) 
8 
(100
%) 
2 
(100
%) 
5 
(55.5
%) 
19 
(53%
), all 
in 
mod
erat
e 
disea
se 
0 17 
(68%
) 
N/A 
WBC
↑ 
3 
(30%
) 
1 
(100
%) 
1 
(100
%) 
0 3 
(9.7
%) 
0 0 0 0 0 2 
(100
%) 
0 2 
(25%
) 
0 0 0 0 0 N/A 
WBC
↓ 
1 
(10%
) 
0 0 7 
(15%
) 
2 
(6.5
%) 
0 0 0 1 
(100
%) 
0 0 0 1 
(12.5
%) 
0 3 
(33%
) 
7 
(19.4
%) 
0 0 N/A 
Lym
phoc
ytes 
↑ 
1 
(10%
)↑ 
N/A 1 
(100
%) 
N/A 4 
(12.9
%) 
N/A N/A 0 0 0 N/A 0 0 0 0 11 
(30.5
%)↓ 
0 0 N/A 
Lym
phoc
ytes 
↓ 
0 N/A 0 N/A 2 
(6.5
%) 
N/A N/A 0 1 
(100
%) 
0  0 1 
(12.5
%) 
0 0  0 0 N/A 
HB↓ 0 N/A 1 
(100
N/A N/A 0 0 N/A N/A 0 0 0 3 
(37.5
N/A 5 
(55%
N/A 0 N/A N/A 
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%) %) ) 
PLT
↑ 
2 
(20%
) 
0 0 N/A 2 
(6.5
%) 
1 
(100
%) 
1 
(100
%) 
0 0 0 2 
(100
%) 
0 2 
(25%
) 
N/A 0 N/A 0 N/A N/A 
PLT
↓ 
1(10
%) 
1 
(100
%) 
0 N/A 0 0 0 0 1 
(100
%) 
0 0 0 1 
(12.5
%) 
N/A 1 
(11%
) 
 0   
CRP 
↑ 
3 
(30%
) 
1 
(100
%) 
1 
(100
%) 
N/A 3 
(9.7
%), 
N/A 
for 1 
(3.2
%) 
0 0 0 N/A 0 1 
(50%
) 
0 5 
(62.5
%) 
1 
(50%
) 
0 1 
(2.0
%) 
0 N/A, 
medi
an 
14.5
mg/L 
0.91-
25.0
4) 
(Nor
mal: 
<10
ml/L) 
N/A 
ESR 
↑ 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0 N/A N/A 0 0 N/A N/A N/A 
LFT
↑ 
2 
(20%
) 
0 N/A N/A 7 
(22%
) 
N/A N/A 0 N/A 0 2 
(100
%) 
0 3 
(37.5
%) 
0 0 3 
(8.3
% 
0 0 N/A 
 
Currently available datasets are from Chinese cohorts. Most children experienced mild or moderate 
disease, while 133 of 2290 children summarised in table 1 were severely or critically ill (bold italics) 
(5.8%), and 2 died (0.09%). Few children who developed severe COVID-19 did not consistently 
exhibit clinical and/or laboratory signs of cytokine storm syndromes, such as cytopenias, or al tered 
liver function. While data are very limited, this appears to be in contrast to adult cohorts, where 
significant proportions of severely ill patients show signs of cytokine storm syndrome, which is 
associated with poor outcomes 1,9. Abbreviations: WBC: white blood counts, HB: haemoglobin, PLT: 
Platelet counts, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, LFT: liver function tests 
(AST and/or ALT elevation), N/A: not available. 
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Highlights 
 The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions 
of lifes globally 
 Children with COVID-19 rarely develop severe symptoms and mortality is relatively 
low 
 Co-infections (and co-clearance) with other viruses may help children to overcome 
SARS-CoV2 
 Fewer comorbidities and age-specific host factors may protect children 
 Limited experience suggests that pre-existing anti-inflammatory treatment may not 
increase risk significantly 
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